M&T Bank Corp Purchases 13,162 Shares of Sanofi $SNY

M&T Bank Corp raised its position in Sanofi (NASDAQ:SNY) by 3.2% during the 4th quarter, HoldingsChannel reports. The fund owned 425,705 shares of the company’s stock after buying an additional 13,162 shares during the quarter. M&T Bank Corp’s holdings in Sanofi were worth $20,630,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Raymond James Financial Inc. lifted its position in shares of Sanofi by 81.3% in the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock worth $284,058,000 after purchasing an additional 2,635,867 shares in the last quarter. Mondrian Investment Partners LTD acquired a new stake in Sanofi in the 3rd quarter valued at $171,742,000. Natixis Advisors LLC lifted its position in Sanofi by 11.8% during the 3rd quarter. Natixis Advisors LLC now owns 3,113,381 shares of the company’s stock worth $146,952,000 after buying an additional 327,569 shares in the last quarter. Equity Investment Corp lifted its position in Sanofi by 3.0% during the 3rd quarter. Equity Investment Corp now owns 2,587,690 shares of the company’s stock worth $122,139,000 after buying an additional 75,255 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in shares of Sanofi by 19.4% during the 3rd quarter. American Century Companies Inc. now owns 2,338,969 shares of the company’s stock worth $110,399,000 after buying an additional 379,784 shares during the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Sanofi Stock Down 5.9%

Shares of SNY stock opened at $43.35 on Tuesday. Sanofi has a 52-week low of $43.15 and a 52-week high of $55.29. The stock has a market cap of $105.73 billion, a price-to-earnings ratio of 12.11, a PEG ratio of 1.14 and a beta of 0.35. The firm’s 50-day moving average is $46.39 and its 200-day moving average is $47.89. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.22 and a current ratio of 1.01.

Sanofi Increases Dividend

The firm also recently disclosed an annual dividend, which will be paid on Wednesday, June 3rd. Stockholders of record on Monday, May 4th will be given a $2.4225 dividend. The ex-dividend date of this dividend is Monday, May 4th. This is a positive change from Sanofi’s previous annual dividend of $2.04. This represents a dividend yield of 559.0%. Sanofi’s payout ratio is 44.69%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Weiss Ratings cut Sanofi from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, April 29th. Argus raised Sanofi to a “strong-buy” rating in a research report on Monday, April 27th. UBS Group restated a “neutral” rating on shares of Sanofi in a research note on Friday, January 16th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research report on Thursday, March 19th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sanofi in a report on Friday, January 16th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Sanofi presently has an average rating of “Hold” and a consensus price target of $51.00.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.